These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 8864964)
21. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128 [TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. Merkel M; Loeffler B; Kluger M; Fabig N; Geppert G; Pennacchio LA; Laatsch A; Heeren J J Biol Chem; 2005 Jun; 280(22):21553-60. PubMed ID: 15774484 [TBL] [Abstract][Full Text] [Related]
23. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603 [TBL] [Abstract][Full Text] [Related]
24. Fate of apolipoproteins C-1, C-iii, and E during lipolysis of human very low density lipoproteins in vitro. Tam SP; Dory L; Rubinstein D J Lipid Res; 1981 May; 22(4):641-51. PubMed ID: 7276737 [TBL] [Abstract][Full Text] [Related]
25. Very low-density lipoprotein/lipo-viro particles reverse lipoprotein lipase-mediated inhibition of hepatitis C virus infection via apolipoprotein C-III. Sun HY; Lin CC; Lee JC; Wang SW; Cheng PN; Wu IC; Chang TT; Lai MD; Shieh DB; Young KC Gut; 2013 Aug; 62(8):1193-203. PubMed ID: 22689516 [TBL] [Abstract][Full Text] [Related]
26. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. Zheng C; Khoo C; Ikewaki K; Sacks FM J Lipid Res; 2007 May; 48(5):1190-203. PubMed ID: 17314277 [TBL] [Abstract][Full Text] [Related]
27. Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: further evidence for the presence of non-equilibrating pools of apolipoproteins C-II and C-III in plasma lipoproteins. Tornoci L; Scheraldi CA; Li X; Ide H; Goldberg IJ; Le NA J Lipid Res; 1993 Oct; 34(10):1793-803. PubMed ID: 8245727 [TBL] [Abstract][Full Text] [Related]
28. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. Jong MC; Dahlmans VE; van Gorp PJ; van Dijk KW; Breuer ML; Hofker MH; Havekes LM J Clin Invest; 1996 Nov; 98(10):2259-67. PubMed ID: 8941642 [TBL] [Abstract][Full Text] [Related]
29. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism. Medh JD; Fry GL; Bowen SL; Ruben S; Wong H; Chappell DA J Lipid Res; 2000 Nov; 41(11):1858-71. PubMed ID: 11060356 [TBL] [Abstract][Full Text] [Related]
30. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. Batal R; Tremblay M; Barrett PH; Jacques H; Fredenrich A; Mamer O; Davignon J; Cohn JS J Lipid Res; 2000 May; 41(5):706-18. PubMed ID: 10787431 [TBL] [Abstract][Full Text] [Related]
31. Postprandial exchange of apolipoprotein C-III between plasma lipoproteins. Barr SI; Kottke BA; Mao SJ Am J Clin Nutr; 1981 Feb; 34(2):191-8. PubMed ID: 7211723 [TBL] [Abstract][Full Text] [Related]
32. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Jong MC; Dahlmans VE; van Gorp PJ; Breuer ML; Mol MJ; van der Zee A; Frants RR; Hofker MH; Havekes LM Arterioscler Thromb Vasc Biol; 1996 Aug; 16(8):934-40. PubMed ID: 8696956 [TBL] [Abstract][Full Text] [Related]
33. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Shachter NS Curr Opin Lipidol; 2001 Jun; 12(3):297-304. PubMed ID: 11353333 [TBL] [Abstract][Full Text] [Related]
34. Alterations of VLDL composition during alimentary lipemia. Björkegren J; Hamsten A; Milne RW; Karpe F J Lipid Res; 1997 Feb; 38(2):301-14. PubMed ID: 9162750 [TBL] [Abstract][Full Text] [Related]
35. Expression of a novel human apolipoprotein (apoC-IV) causes hypertriglyceridemia in transgenic mice. Allan CM; Taylor JM J Lipid Res; 1996 Jul; 37(7):1510-8. PubMed ID: 8827523 [TBL] [Abstract][Full Text] [Related]
36. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E. Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028 [TBL] [Abstract][Full Text] [Related]
37. Treatment of hypertriglyceridemia by two diets rich either in unsaturated fatty acids or in carbohydrates: effects on lipoprotein subclasses, lipolytic enzymes, lipid transfer proteins, insulin and leptin. Pieke B; von Eckardstein A; Gülbahçe E; Chirazi A; Schulte H; Assmann G; Wahrburg U Int J Obes Relat Metab Disord; 2000 Oct; 24(10):1286-96. PubMed ID: 11093290 [TBL] [Abstract][Full Text] [Related]
38. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content. Khoo C; Campos H; Judge H; Sacks FM J Lipid Res; 1999 Feb; 40(2):202-12. PubMed ID: 9925648 [TBL] [Abstract][Full Text] [Related]
39. Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C. van Barlingen HH; de Jong H; Erkelens DW; de Bruin TW J Lipid Res; 1996 Apr; 37(4):754-63. PubMed ID: 8732775 [TBL] [Abstract][Full Text] [Related]
40. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism. Wolska A; Dunbar RL; Freeman LA; Ueda M; Amar MJ; Sviridov DO; Remaley AT Atherosclerosis; 2017 Dec; 267():49-60. PubMed ID: 29100061 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]